4th AML Academy 2021
Study Alliance Leukemia – AML Cooperative Group – CELL

online via Zoom
18th/19th November 2021

Dear members of the SAL and AML-CG study groups,
Dear members of CELL,

we are very pleased to invite you to the 4th AML Academy and the autumn meeting of the SAL and AML-CG study groups in Dresden on 18th – 19th November 2021. Due to the current figures and especially the situation in Saxony, we decided at short notice to hold the conference exclusively virtually. Although we would have been delighted to meet with you in person, we guess we'll have to hope for an improvement next spring. Even if we can not meet on site we will exchange information and talk about the latest developments in the research field of AML about the current status of our SAL and AML-CG studies via Zoom.

We kindly ask you to register as soon as possible at


We are looking forward to welcoming you via Zoom.

Kind regards,

Prof. Dr. med. Christoph Röllig
Medizinische Klinik und Poliklinik I, Universitätsklinikum Dresden

Thursday, 18th November 2021

13:00 – 13:15

AML Academy I

An old mystery of new interest: What is BPDCN?
PD Dr. med. Marco Herling

13:45 – 14:05
CPX-351: Real-World-Data
Dr. med. Moritz Middeke

14:15 – 14:35
IDH mutations and novel treatment options
Prof. Dr. med. Claudia Baldus

14:45 – 15:05
Aplastic Syndromes and AML
PD Dr. med. Fabian Beier

15:15 – 15:35
Blood Transfusions – Controversies or Common Standards?
Dr. med. Kerstin Schäfer-Eckart

AML Academy II

16:15 – 16:35
Conditioning – any hope for standardization?
Prof. Dr. med. Andrea Bacigalupo

16:45 – 17:05
Maintenance – Revival of an old concept?
Prof. Dr. med. Andrea Craddock

17:30 – 18:00
How I treat newly diagnosed AML
Prof. Dr. med. Norbert Vey

18:15 – 18:45
How I treat newly diagnosed AML
M.D. Amir T. Fathi

Friday, 19th November 2021

SAL Steering Committee Meeting

08:00 – 10:00

Joint Study Group Meeting of SAL, AML-CG, CELL

11:00 – 12:00
Updates on current, past and future projects and trials

Lunch Break

13:00 – 15:00
Updates on current, past and future projects and trials


M.D. Andrea Bacigalupo, Policlinico Gemelli, Rom, Italy

Prof. Dr. med. Claudia Baldus, Universitätsklinikum Schleswig-Holstein, Germany

PD Dr. med. Fabian Beier, Universitätsklinikum Aachen, Germany

Professor Charles Craddock, University Hospital Birmingham, United Kingdom

M.D. Amir T. Fathi, Harvard Medical School, Boston, USA

PD Dr. med. Marco Herling, Universitätsklinikum Leipzig, Germany

Dr. med. Moritz Middeke, Universitätsklinikum Dresden, Germany

Dr. med. Kerstin Schäfer-Eckart, Klinikum Nürnberg Nord, Germany

M.D. Norbert Vey, Aix-Marseille University, Marseille, France

AbbVie Deutschland GmbH & Co. KG präsentiert:

Astellas Pharma GmbH präsentiert:

Astellas Pharma GmbH, München, ist die deutsche Tochtergesellschaft der weltweit tätigen Astellas Pharma Inc. mit Sitz in Tokio. Die europäische Zentrale, Astellas Pharma Europe Ltd. befindet sich in London, UK.

Astellas ist ein forschungsorientiertes pharmazeutisches Unternehmen, das sich mit innovativen und bewährten Arzneimitteln dem Ziel Changing Tomorrow verschrieben hat. Astellas arbeitet tagtäglich daran, durch die Bereitstellung und den Zugang zu innovativen Arzneimitteln einen spürbaren Mehrwert für Patienten und deren Angehörige zu schaffen.

Bei der Forschung und Entwicklung neuartiger Arzneimittel fokussiert sich Astellas auf die Therapiegebiete Onkologie, Anti-Infektiva, Urologie und Transplantation.

Novartis Pharma AG präsentiert:

Bristol Myers Squibb präsentiert:

Stemline präsentiert:

BeiGene präsentiert:


Prof. Dr. med. Christoph Röllig
Prof. Dr. med. Martin Bornhäuser

Universitätsklinikum Carl Gustav Carus Dresden
Medizinische Klinik und Poliklinik der TU Dresden
Fetscherstraße 74
01307 Dresden


Freiberger Straße 33
01067 Dresden

Meeting times

AML Academy
Thursday, 18th November 2021
13:00–19:00 h

SAL autumn meeting
Friday, 19th November 2021
08:00–10:00 h SAL Steering Committee Meeting
10:30–15:00 h Joint Study Group Meeting of SAL, AML-CG, CELL

Online via Zoom

Juliana Binder
project manager

Mobile: +49 151 23 33 79 72
Phone: +49 351 25 933 211

Fachbereich Medizin

Tatzberg 47/49
01307 Dresden

Abbvie Deutschland GmbH (20.000 €), Amgen GmbH (5.000 €), Astellas Pharma GmbH (5.000 €), BeiGene Germany GmbH (5.000 €), Bristol-Myers Squibb GmbH & Co. KGaA (20.000 €), Jazz Pharma GmbH (30.000 €), Neovii Biotech GmbH (5.000 €), Stemline Therapeutics Switzerland GmbH (20.000 €),

We like to thank the sponsors for their contributions. The stated amounts are charged exclusively for advertising purposes and stand costs. If you are interested in sponsoring, please contact the event management.

The sponsors that are subject to the FSA code are based on the FSA code, which obliges to transparency. The monetary benefits are documented and published on their website.